Given Brainomix's success in developing imaging biomarkers for Stroke and Interstitial Lung Disease (ILD), future research and development will expand the Brainomix 360 platform to include a Cancer solution, with a focus on improving treatment response assessment in Oncology.
Brainomix’s Cancer solution has been trained to characterize and quantify solid-tumors using thousands of cases from leading academic institutions, unlocking objective measurement of tumor lengths, and other biomarkers such as tumor volume.
Efficacy detection, as an adjunct to traditional human-derived measures such as RECIST
Blinded Independent Central Review (BICR) with AI-powered objectivity and standardization
Objective assessment and comparison of early-stage treatments
Reduced sample sizes and faster trial execution
Speak with us to learn how to integrate our oncology biomarkers into your clinical trials and clinical research.
I have read the Brainomix privacy policy
I would like to receive information about products or services from Brainomix